AVBP – arrivent biopharma, inc. (US:NASDAQ)
Stock Stats
News
ArriVent BioPharma: Bringing A Novel Cancer Drug From China [Seeking Alpha]
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at Citigroup Inc. from $30.00 to $36.00. They now have a "buy" rating on the stock.
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $39.00 price target on the stock, up previously from $35.00.
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $38.00. They now have a "buy" rating on the stock.
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at HC Wainwright from $30.00 to $36.00. They now have a "buy" rating on the stock.
Form SC 13G ArriVent BioPharma, Inc. Filed by: Sofinnova Venture Partners XI, L.P.
Form SC 13G ArriVent BioPharma, Inc. Filed by: FMR LLC
Form SC 13G ArriVent BioPharma, Inc. Filed by: BlackRock, Inc.
Form SC 13G ArriVent BioPharma, Inc. Filed by: BlackRock, Inc.
Form SC 13G ArriVent BioPharma, Inc. Filed by: Octagon Capital Advisors LP
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.